SEC Form 4 · accession 0001209191-18-035400
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lyndal K. Hesterberg
Officer — Sr VP, Research & Development
Period of report
May 23, 2018
Accepted (ET)
Jun 4, 2018 · 8:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $2.35 | May 23, 2018 | A | 150,000 | A | — | May 22, 2028 | Common Stock | 150,000 | 150,000 | D |
| Option to Purchase Common StockF2 | $4.70 | holding | — | — | — | — | Feb 16, 2027 | Common Stock | 14,400 | 14,400 | D |
| Option to Purchase Common StockF2 | $4.05 | holding | — | — | — | — | Oct 31, 2026 | Common Stock | 125,000 | 125,000 | D |
| Option to Purchase Common StockF3 | $3.06 | holding | — | — | — | — | Feb 15, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- F2One quarter of the options vested on October 31, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- F3One quarter of the options vested on February 15, 2017 and one quarter vested on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.